In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

The Philadelphia-based biotech, founded and run by Jim Wilson, M.D., Ph.D., will receive up to $100 million from the Oswaldo ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

Several months after forging a fresh path forward for its troubled Friedreich ataxia (FA) drug vatiquinone, PTC Therapeutics ...

The patient was in his 60s, an African American man with emphysema. | State attorneys general and U.S. senators have pressed ...

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...

Medtronic has been notifying users of its MiniMed insulin pumps to be aware of potentially shortened battery lives, and to ...

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. | Mestag ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

The FDA has given a green light to an at-home test that checks for both COVID-19 and the flu—a first for the agency, outside ...

Black Diamond Therapeutics has deprioritized one of its two clinical-stage lung cancer contenders, jettisoned two executives ...